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Abstract 
Few pooled analyses of anti-resorptive (AR) treatment trials are available that relate short-term changes in 
bone turnover markers (BTMs) to fracture reduction. Such information would be useful to assess new ARs or 
novel dosing regimens. 
 
In the FNIH Bone Quality project, we received and analysed individual-level data from 28,000 participants 
enrolled in 11 bisphosphonate (BP) and 3 selective estrogen receptor modulator (SERM) placebo-controlled 
fracture endpoint trials. Using BTM results for 2 bone formation markers (bone specific alkaline phosphatase 
[bone ALP] and pro-collagen I N-propeptide [PINP]) and 2 bone resorption markers (N- and C-terminal 
telopeptide of type I collagen) and incident fracture outcome data, we performed a meta-regression relating 
the mean net effect of treatment on change in bone turnover (active minus placebo percent difference after 
3-12 mo.) to the log of studywide fracture risk reduction, and used linear regression to plot the best fitting 
line.  Separate analyses were performed for incident morphometric vertebral, non-vertebral and hip fractures 
over 1-4 yr. of follow-up.   
 
Change in bone ALP and PINP were available for over 16,000 and 10,000 participants, respectively. For 
vertebral fracture, the results showed a strong relationship between treatment-related bone ALP or PINP 
changes and vertebral fracture risk reduction [r2=0.82 (p<0.001) and 0.75 (p=0.011), respectively] 
Relationships were weaker and no longer statistically significant for non-vertebral [r2=0.33 (p=0.053) and 0.53 
(p=0.065), respectively] and hip fracture [r2=0.17 (p=0.24) and 0.43 (p=0.11), respectively] outcomes.  Analyses 
limited to BP trials gave similar results. For all fracture types, relationships were weaker and non-significant for 
bone resorption markers.  
 
We conclude that short-term AR treatment-related changes in bone ALP and PINP strongly predict vertebral 
fracture treatment efficacy, but not non-vertebral or hip fracture treatment efficacy.  Change in bone 
formation markers might be useful to predict the anti-vertebral fracture efficacy of new AR compounds or 
novel dosing regiments with approved AR drugs. 
 
Word count: 298  
  
Introduction  
Short term changes in bone turnover markers (BTM) are typically assessed in randomised controlled trials of 
drugs being developed for osteoporosis. In the early phases of clinical trial development, they may be useful in 
selecting the optimal dose to take forward to Phase III and once the dose and dosing regime is established 
they provide insight into the mechanism of action of the drug. The commonest mechanism of action for 
ƚŚĞƌĂƉŝĞƐĨŽƌŽƐƚĞŽƉŽƌŽƐŝƐŝƐƚŽŝŶŚŝďŝƚďŽŶĞƌĞƐŽƌƉƚŝŽŶ ? ‘ĂŶƚŝ-ƌĞƐŽƌƉƚŝǀĞ ? ?Z )ĂŶĚƐŽƚŚĞƐĞĚƌƵŐƐƌĞƐƵůƚŝŶ
decreases in bone resorption markers. They reduce the rate of bone remodelling and as the process of bone 
formation is coupled to bone resorption then, after a delay of about a month, there is a reduction in bone 
formation markers. The lowering of levels of BTMs to levels found in healthy young women (or below) is 
believed to be one mechanism whereby anti-resorptive therapy reduce the risk of fracture1, 2. 
 
Different anti-resorptive drugs reduce bone turnover markers to different extents. Within clinical trials, there 
is some evidence that the greater the reduction in bone turnover within an individual, the greater the 
reduction in fracture risk3. Such evidence is available for selective oestrogen receptor modulators (SERMs)4,5,6 
and bisphosphonates administered orally7,8 or intravenously9,10. Only one analysis11 has pooled multiple AR 
treatment trials to establish a more robust relationship between short-term changes in BTM and fracture 
reduction.  If strong and reproducible relationships between change in BTMs and fracture outcomes exist, 
prior to initiating large and expensive fracture endpoint trials for new ARs, or when assessing novel AR dosing 
regiments for established ARs, it might be useful to assess the effects of treatment on BTMs to predict the 
likely fracture outcome and select the optimal dose.  
 
A 2002 meta-regression11 that pooled the published results from 18 AR trials found that a 50% reduction in 
various bone formation markers (vs. placebo) predicted a 44% risk reduction in non-vertebral fracture over 2-5 
years, but vertebral and hip fractures were not assessed.  Further, in that meta-regression the specific BTMs 
and analytic approach varied between studies.  Since 2002 additional large trials with other BPs (zoledronic 
acid12, ibandronate13 and SERMS (basedoxifene14, lasofoxifene15, arzoxifene16) have been completed.  
 
To determine the relationship between short-term treatment-related changes in bone turnover markers and 
study-level fracture risk reduction, we systematically collected individual level data from existing placebo-
controlled trials of AR agents (both bisphosphonates and SERMs) to perform a meta-regression.  The goal of 
such a meta-regression, which plots the average short-term treatment-related changes in BTM against the 
  
observed study-level reduction in fractures, is to determine how well short-term changes in BTMs predict 
fracture outcomes.   
 
Methods 
Study data 
A systematic search through published literature was made to identify any study that met the following 
criteria:  placebo-controlled randomized trial of osteoporosis medication with a fracture endpoint.  Studies 
targeting specific medical conditions (e.g. rheumatoid arthritis) and treatments (e.g., corticosteroid users) 
were excluded.  We then attempted to collect the complete data files, including individual subject-level data, 
from the study sponsors. Within each sponsor, we attempted to identify an individual who was knowledgeable 
about the study.  In many cases, the medications have now become available as generics  or the companies 
had merged with others, making contact more difficult.  Once a contact was established, we established a 
contract for transfer of the data and a data use agreement. We also sought data documentation including 
study protocol, data specifications, clinical study reports and annotated forms.   
The list of studies for which we could acquire data ƚŚĂƚŝŶĐůƵĚĞĚdD ?Ɛis shown in Table 1 and includes most 
osteoporosis medication studies including drugs that were eventually approved as well as others for which 
regulatory approval was not sought or received.  As our original intention was to include all anti-resorptive 
agents, we requested densoumab data from the sponsor, but due to the low number of patients with serial 
bone marker samples in the densoumab fracture trial (n=80 per group)17 a meaningful analysis was not 
considered possible.  
Conversion of studies to standard data template 
A standard data template was established into which all studies were converted. In brief, this data template 
included a file for each of the following types of data: baseline demographics, bone turnover markers, DXA, 
QCT/finite element, clinical fractures and vertebral fractures.  Each study was converted to the standard 
format.  Some data sought (e.g., parental history of hip fracture) was available in some, but not all, studies.  
Fracture outcomes 
The study focused on creating a standardized definition for fracture outcomes.  If possible given the data, we 
excluded fractures due to major trauma (i.e., trauma sufficient to case a fracture in a young, normal 
individual). For some of the studies, only the predefined categories for that study were available so that some 
  
of these subcategories could not be defined.  The time to first non-vertebral fracture of each type was 
calculated.  For vertebral fractures, we used the individual study definitions based on a comparison of a 
baseline with one or more follow-up lateral spine radiographs.  Definitions of an incident vertebral fracture 
varied somewhat across studies.  These definitions are either based on quantitative morphometry (QM), semi-
quantitative assessment (SQ)18 or a combination of these criteria.  For studies that assessed morphometric 
vertebral fracture on more than one occasion, we used the fracture data from the final study evaluation.  
Based upon the available study data, we then used the fracture outcomes in each trial to define the relative 
hazard (RH) for non-vertebral and hip fracture in treatment vs. placebo and the odds ratio (OR) for incident 
morphometric vertebral fracture.  Note that in some cases, for various reasons the RH or OR varies slightly 
from the original published results. 
Assays for bone turnover markers 
The assays made on blood samples (bone ALP, PINP, and sCTX) all used serum, not plasma. Different assays 
were used to measure the bone formation markers (bone ALP and PINP) and the bone resorption markers 
(NTX/Cr, sCTX) as described in Table 2. The assays for bone ALP included an immunoradiometric assay (Ostase, 
Hybritech, La Jolla, CA), a wheat-germ lectin precipitation assay19, an autoanalyser method (Beckman-Coulter 
Inc, San Diego, CA) and the Alkphase B ELISA assay (Metra Biosystems Inc, Mountain View, CA). The assay for 
PINP included a radioimmunoassay (Orion Diagnostica, Espoo, Finland) and an automated immunoassay 
analyser method (Roche Elecsys 2010, Penzburg, Germany). The assays for urine NTX included an ELISA 
(Osteomark, Ostex International Inc, Seattle WA) and an automated immunoassay analyser method (Vitros 
ECi, Ortho Clinical Inc, Rochester, NY). The urine collections were generally made as second morning voids and 
the NTX result was expressed as a ratio to the creatinine concentration (NTX/Cr). The assays for sCTX included 
an ELISA (CrossLaps, Nordic Bioscience Diagnostics AS, Herlev, Denmark) and an automated immunoassay 
analyser (Roche Elecsys 2010, Penzburg, Germany). Other bone turnover measurements were made in a few 
of the trials, but are not included here, and these included osteocalcin, urinary sCTX and deoxypyridinoline. 
We chose not to include these markers as they did not include the two markers recommended by the 
International Osteoporosis Foundation and International Federation of Clinical Chemistry3 or else they had 
fewer studies in which they were measured. 
Data analysis 
Our overall goal of this analysis is to assess the relationship, across studies, between short-term net change in 
bone turnover marker and longer-term fracture reduction. For most studies, we analyzed the change in 
  
marker from baseline to 3 months.  For 4 studies for which 3 month BTM values were not available, we used 
12 month values (Table 2) ?&ŽƌƚŚĞ,KZ/KEW&dƐƚƵĚǇŽĨŽůĞĚƌŽŶŝĐĂĐŝĚǁŚĞƌĞdD ?ƐĐŚĂŶŐĞŽǀĞƌƚŝŵĞĂĨƚĞƌ
infusion, we used the 6 month BTM value. For each BTM we calculated the median percent change from 
baseline to the follow-up value (as the data were not normally distributed). For studies reporting multiple 
doses, the active treatment groups were combined regardless of dose.  We used Cox and logistic models to 
estimate the effect of assignment to active treatment on clinical and vertebral fractures, respectively. Both the 
BTMs and fractures were analysed by ITT, ignoring adherence to treatment. 
We then plotted the log hazard or odds ratio for the 3 primary types of fractures (vertebral, non-vertebral, 
hip) against the net median % change in BTM (treatment minus the placebo group).  Each study was plotted as 
a circle with the size proportional to the inverse of the variance of the log of the hazard or odds-ratio. Thus, 
larger circles represent studies with more fractures. 
Next, we used a linear model to estimate the effect of the median % change in the BTM on the log hazard or 
odds ratio for each study, again weighted by the inverse of the variance of each outcome.  Finally, we added a 
line interpolating the exponentiated fitted values to the plot described above.  From these regressions we also 
calculated the r2 with 95% confidence intervals, and for those with statistically significant relationships, 
estimated the calculated net change in BTM and associated fracture risk reductions defined by the smallest 
and largest net effects on change in each BTM.  
Results 
Characteristics of included trials 
Patient level data was successfully collected for 14 randomized trials, including 11 bisphosphonate (5 
alendronate, 3 risedronate, 2 ibandronate and 1 zoledronic acid) and 3 SERM studies (raloxifene, arzoxifene 
and lasofoxifene, 1 each) (Table 1).  Parenteral study medication or placebo was given every 3-12 months in 2 
BP trials. Trial size ranged from 240 to over 9300 participants and trial duration ranges from 1 to 4 years of 
follow-up.  Most of the trials enrolled postmenopausal women (13) and 1 trial only enrolled men. 
 
Treatment-related changes in BTMs 
After pooling individual trials we had paired measurements for bone ALP and PINP in 16,087 and 10,335 
subjects, respectively. We had measurements for urinary NTX/Cr and serum sCTX in 6,722 and 8,006, 
respectively (Table 3).  Studies varied as to which subset of participants had BTM assessments and which 
  
dD ?ƐǁĞƌĞmeasured, and therefore the  various BTM and fracture analyses reported here are not 
necessarily among the same studies or the same study participants. 
 
BTM percent changes in the active treatment groups were larger for some markers than others; for example, 
the maximum reduction in bone ALP was 39% but for sCTX it was 69% (Table 2).  Reductions in BTMs were also 
observed in the placebo-treated participants. 
 
In general, the greater the net reduction in BTMs the greater the reduction in the risk of fractures, and this 
was more striking for bone formation (Figure 1) than bone resorption markers (Figure 2). 
 
Extrapolating from observed effects on change in BTM and vertebral fracture risk reduction (Figure 3), we 
found that a 12% net reduction in bone ALP would predict a 33% reduction in vertebral fracture risk, while a 
30% net reduction in bone ALP would predict a 65% reduction in fracture risk.  Similarly, a 22% net reduction 
in PINP would predict a 30% reduction in vertebral fracture risk, while a 50% net reduction in bone ALP would 
predict a 62% reduction in fracture risk. 
  
Meta-regression results 
The overall meta-regression results, quantified by variance explained (r2) with 95% confidence intervals and 
statistical significance are shown in Table 4.  The point estimates for r2 were higher for bone ALP and PINP but 
the confidence intervals are wide. The associations for non-vertebral and hip fracture were not statistically 
significant, again with wide confidence intervals, but for vertebral fracture both bone formation markers were 
associated significantly. 
 
We further tested whether the higher r2values seen with bone formation markers was due to older vs. more 
recent trials by taking the 5 contemporary trials that included both PINP and sCTX.  In a meta-regression 
limited to those 5 contemporary trials, the R-squared values for vertebral, non-vertebral and hip fracture for 
PINP were 0.74 (p=0.06), 0.44 and 0.54 (both p>0.15), respectively, whereas the values for sCTX were 0.62, 
0.47 and 0.20, respectively (all p>0.05).   
 
Sensitivity analyses 
We performed several sensitivity analyses to test the robustness of our results.  Analyses limited to a single 
Bone ALP assay (Ostase Tandem IRMA) and a single NTX/Cr assay (Ostemark ELISA) gave similar results to 
  
those that pooled several different assays (Table 4).  Similarly, analyses limited to just bisphosphonates 
generated results similar to analyses conducted for all AR trials (data not shown).  
 
Discussion 
In this pooled meta-regression of individual level data collected from 14 AR trials, greater short-term 
treatment-related reductions in two formation BTMs, bone ALP and PINP, were associated with greater 
reductions in vertebral fracture during follow-up. We found no significant relationship between short term 
changes in NTX/Cr or sCTX and any fracture outcome.  None of the BTMs were significantly associated with 
non-vertebral or hip fracture risk. 
 
Bone ALP was available on the largest number of trial participants.  The robust relationship between changes 
in bone ALP and incident vertebral fractures might be useful for future AR drug development or assessment of 
novel dosing regiments for existing ARs.  For example, as shown in Figure 3 if a hypothetical new AR reduced 
bone ALP by 30% it would be expected to reduce vertebral fractures by 65%, while a new AR that only reduced 
bone ALP by 12% would be expected to reduce vertebral fractures by 33%.   
 
It was notable that bone formation markers appeared to be at least as good as bone resorption, according to 
the magnitude of the r2 value (Table 4). Of course, the anti-resorptives work by the inhibition of bone 
resorption, but bone formation subsequently decreases due to the phenomenon of coupling. The reasons why 
there are stronger relationships with the bone formation markers is that these tend to be less variable and 
less affected by  meal times and circadian rhythm than bone resorption markers3. However, the bone 
formation markers were measured in more subjects than the bone resorption markers which may also be 
partially responsible for the stronger relationship for formation markers.  Similarly, compared to vertebral 
fracture outcomes, changes in bone turnover markers were less strongly associated with both non-spine and 
hip fractures, perhaps making a significant correlation more difficult to observe as a result of the generally 
lower risk reductions for these outcomes.  
 
It should be noted that these findings only relate to anti-resorptive treatments. Anabolic treatments such as 
teriparatide increase bone formation markers (and sometimes bone resorption markers) and so observed 
relationship are likely to be different. Unlike anti-resorptive and anabolic therapies, formation sparing 
resorption inhibitors20 such as odanacatib result in a long-term decrease in bone resorption but not bone 
formation, and yet odanacatib treatment reduces the risk of both vertebral and non-vertebral fractures21. 
  
 
We recognise that our study has several additional limitations. Not all subjects had bone turnover markers 
measured and a different set of studies had data for each BTM.  Not all trials included all bone turnover 
markers and studies with men were available. The assays for the bone turnover markers differed; we were 
unable to find any study that compared two assays for the same marker for the treatments we have reported 
here. Also the timing of sampling during the trials differed, varying from 3 to 12 months on treatment. The 
sample for sCTX was not always obtained in the fasting state; this is important as CTX has a circadian rhythm 
with the lowest values in the afternoon.  Lastly, there were too few denosumab BTM and fracture data to 
include in our analyses. 
 
The findings from this study-level meta-regression are broadly consistent with observations made in individual 
anti-resorptive trials of the relationship between short term change in BTM and fracture risk reduction in a 
single  participant. These studies have included trials of selective estrogen receptor modulators (SERMs)4,5,6 
and bisphosphonates administered orally7,8 or intravenously9,10.  To better determine the clinical utility of 
serial BTM measurements for a specific patient, we are currently using this large dataset to conduct analyses 
that examine pooled individual level BTM data and fracture outcomes.  These analyses utilize analytic 
approaches, such as the proportion of treatment effect explained (or PTE), that better reflect the relationship 
between short term treatment-related BTM changes and subsequent fractures in individuals.  In addition, it 
will be interesting to determine through future analyses if these relationships are strengthened or differ for 
drugs with different mechanisms of action from that of the anti-resorptives.  
 
In summary, in this pooled meta-regression of multiple anti-resorptive trials we found that greater short term 
reductions in two bone formation markers were strongly associated with subsequent vertebral fracture 
outcomes.  We believe that our meta-regression results may be helpful in the future development of anti-
resorptive drugs for osteoporosis, particularly in choosing the dose and treatment schedule. They may allow 
prediction of the fracture risk reduction from small, short term randomised clinical trials and this might 
encourage the development of additional effective drugs for fracture prevention.  
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Table 1. Characteristics of Placebo-Controlled Fracture Endpoint Trials Included in Meta-Regression. 
 
^ƚƵĚǇEĂŵĞ 
 ?zĞĂƌŽĨƚƌŝĂů
ƌĞƉŽƌƚ ? 
 
^ƚƵĚǇƌƵŐ 
 
EdŽƚĂů 
 
 
 
ŐĞ ?ŵĞĂŶ ? ?
ŐĞŶĚĞƌ ?A㤀 
ǁŽŵĞŶ ? 
 
 
DĞĂŶ
&ŽůůŽǁ ?ƵƉ
 ?ŵŽŶƚŚƐ ? 
Baseline 
Femoral 
Neck T-score 
(mean) 
 
 
WƌĞǀĂůĞŶƚ
sĞƌƚĞďƌĂů
&ƌĂĐƚƵƌĞĂƚ
ĂƐĞůŝŶĞ ?A㤃? 
 
&ƌĂĐƚƵƌĞ
KƵƚĐŽŵĞƐ ?E ?
sĞƌƚĞďƌĂů ? 
EŽŶ ?
sĞƌƚĞďƌĂů ?,ŝƉ 
 
>EW,^ ? 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ  ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.15  ? ? ? ?  ? ?  ? ? ? ? 
&/d
sZdZ>
&ZdhZ 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.44  ? ? ?  ? ? ? ? ? ? ? ? ? ? 
&/d>/E/>
&ZdhZ 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.21  ?  ? ? ? ? ? ? ? ? ? ? 
&K^/d 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ  ? ? ? ?  ? ? ? ? ? ? ? ?11.4 -1.97 -- --/52/4 
DE ?^^dhz 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ  ? ? ?  ? ? ? ? ? ? 22.4 -2.15 50.2 11/--/-- 
KE 
(2004 13) 
/ďĂŶĚƌŽŶĂƚĞ
 ?ŽƌĂů ) 
 ? ? ? ?  ? ? ? ? ? ? ? ?29.9 -2.10 93.6 167/229/21 
/E/s 
 ? ? ? ? ? ? ? ) 
/ďĂŶĚƌŽŶĂƚĞ
 ?ŝ ?ǀ ? ) 
 ? ? ? ?  ? ? ? ? ? ? ? ?34.0 -2.14 98.4 274/243/26 
,/W 
 ? ? ? ? ? ? ? ) 
ZŝƐĞĚƌŽŶĂƚĞ  ? ? ? ?  ? ? ? ? ? ? ? ?24.9 -2.75 31.0 497/913/205 
sZd ?EKZd, 
DZ/ 
 ? ? ? ? ? ? ? ) 
ZŝƐĞĚƌŽŶĂƚĞ  ? ? ? ?  ? ? ? ? ? ? ? ?27.8 -2.21 78.1 180/157/15 
sZd ?Dh>d/ ?
Ed/KE> 
 ? ? ? ? ? ? ? ) 
ZŝƐĞĚƌŽŶĂƚĞ  ? ? ?  ? ? ? ? ? ? ? ?28.7 -2.40 94.1 166/100/17 
  
,KZ/KE
 ? ? ? ? 
 ? ? ? ? ? ? ? ) 
ŽůĞĚƌŽŶŝĐĂĐŝĚ
 ?ŝ ?ǀ ? ) 
 ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.71  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? 
DKZ 
 ? ? ? ? ? ? ? ) 
ZĂůŽǆŝĨĞŶĞ ?  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.30  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? 
'EZd/KE^ 
 ? ? ? ? ? ? ? ) 
ƌǌŽǆŝĨĞŶĞ ?  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -1.87  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? 
WZ> 
 ? ? ? ? ? ? ? ) 
Lasofoxifene ?  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? -2.19  ? ? ? ?  ? ? ? ? ? ? ? ? ? ? 
*Selective Estrogen Receptor Modulator (SERM) 
Dashes indicate that no data was available.
  
Table 2. Median BTM Baseline (BL) and % Change in Fracture Endpoint Trials. The references relate to the description of the BTM assays and the 
numbers in parentheses describe the assay method (see footnote). 
 
 
  
 
 
BTM 
timing, 
months 
ŽŶĞ>W W/EW Edy ?ƌ Ɛdy 
^ƚƵĚǇEĂŵĞ
 ?zĞĂƌdDĂƐƐĂǇ
ƌĞƉŽƌƚĞĚ ? ^ƚƵĚǇƌƵŐ BL, 
ng/mL 
or IU/L  
% Change 
BL, 
ng/mL 
% Change BL, 
nmol/mmol 
Cr 
% Change 
BL, 
ng/mL 
% Change 
  ĐƚŝǀĞ WK ĐƚŝǀĞ PBO Active PBO Active PBO 
>EW,^ ? 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ 
3 17.0 (1)  ? ? ? ? ?  ? ? ? ? ?  ? ?  ? ?  ? ?  ? ? ? ? ? ? )  ? ? ? ? ?  ? ? ? ? ?  ? ?  ? ?  ? ? 
&/dsZdZ>
&ZdhZ 
 ? ? ? ? ? ?  ? ? ? ?
 ? ? ) 
ůĞŶĚƌŽŶĂƚĞ 
12 13.2 (1)  ? ? ? ? ?  ? ? ? ? ? 47.6 (5)  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ? ? )  ? ? ? ? ?  ? ? ? ? ? 0.29 (9)  ? ? ? ? ?  ? ? ? ? ? 
&/d>/E/>
&ZdhZ 
 ? ? ? ? ? ?  ? ? ? ?
 ? ? ) 
ůĞŶĚƌŽŶĂƚĞ 
12 12.9 (1)  ? ? ? ? ?  ? ? ? ? ? 49.1 (5)  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ? ? )  ? ? ? ? ?  ? ? ? ? ? 0.31 (9)  ? ? ? ? ?  ? ? ? ? ? 
&K^/d 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ 
3 12.3 (1)  ? ? ? ? ? -9.7  ? ?  ? ?  ? ? 54.8 (7) -69.0 -18.1  ? ?  ? ?  ? ? 
DE ?^^dhz 
 ? ? ? ? ? ? ? ) 
ůĞŶĚƌŽŶĂƚĞ 
3 12.1 (1)  ? ? ? ? ? -4.1  ? ?  ? ?  ? ? 33.0 (7) -49.0 -2.9  ? ?  ? ?  ? ? 
KE 
 ? ? ? ? ? ? ? ) 
/ďĂŶĚƌŽŶĂƚĞ ?ŽƌĂů ) 
3 40.0 (2)  ? ? ? ? ? -7.7  ? ?  ? ?  ? ? 57.0 (7) -46.7 -22.7  ? ?  ? ?  ? ? 
/E/s /ďĂŶĚƌŽŶĂƚĞ ?ŝ ?ǀ ? ) 3 51.0 (2)  ? ? ? ? ? -14.3  ? ?  ? ?  ? ? 68.0 (7) -35.7 -30.2  ? ?  ? ?  ? ? 
  
 ? ? ? ? ? ? ? ) ?^Z
 ?ď ) 
,/W ZŝƐĞĚƌŽŶĂƚĞ 3 11.9 (1)  ? ? ? ? ? -9.8  ? ? ? ? ? ? ) ? ? ? ? ?  ? ? ? ? ? 56.9 (8) -50.9 -21.9  ? ?  ? ?  ? ? 
sZd ?EKZd,
DZ/ 
 ? ? ? ? ? ? ? ? ? ? ? ?
 ? ) 
ZŝƐĞĚƌŽŶĂƚĞ 
3 13.3 (1)  ? ? ? ? ? -13.6  ? ?  ? ?  ? ? 63.6 (8) -50.8 -22.0  ? ?  ? ?  ? ? 
sZd ?Dh>d/ ?
Ed/KE> 
 ? ? ? ? ? ? ? ? ? ? ? ?
 ? ) 
ZŝƐĞĚƌŽŶĂƚĞ 
3 12.4 (1)  ? ? ? ? ? -2.5  ? ?  ? ?  ? ? 75.6 (8) -48.1 -19.6  ? ?  ? ?  ? ? 
,KZ/KE ? ? ? ?
 ? ? ? ? ? ?) 
ŽůĞĚƌŽŶŝĐĂĐŝĚ
 ?ŝ ?ǀ ? ) 6/12 (a) 13.2 (3)  ? ? ? ? ?  ? ? ? ? 49.4 (6)  ? ? ? ? ?  ? ? ? ? ?  ? ?  ? ?  ? ? 0.37 (6)  ? ? ? ? ?  ? ? ? ? ? 
DKZ 
 ? ? ? ? ? ?) 
ZĂůŽǆŝĨĞŶĞ ? 
6/12 (a) 15.8 (1)  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ? ? ) ? ? ? ? ?  ? ? ? ? ?  ? ?  ? ?  ? ?  ? ?  ? ?  ? ? 
'EZd/KE^
 ? ? ? ? ? ? ? ) 
ƌǌŽǆŝĨĞŶĞ ? 
3  ? ?  ? ?  ? ? 48.9 (5)  ? ? ? ? ?  ? ? ? ?  ? ?  ? ?  ? ? 0.57 (9)  ? ? ? ? ?  ? ? ? ? 
PEARL  
(201234) 
Lasofoxifene* 
3 22.6 (4)  ? ? ? ? ?  ? ? ? ? 48.7 (6)  ? ? ? ? ?  ? ? ? ?  ? ?  ? ?  ? ? 0.42 (6)  ? ? ? ? ?  ? ? ? ? 
*Selective Estrogen Receptor Modulator (SERM) 
 
Assays: 
Bone ALP, (1) Ostase Tandem IRMA (ng/mL), (2) Wheat germ lectin precipitation (IU/L), (3) Beckman autoanalyser (ng/mL), (4) Alkphase B ELISA (IU/L). 
PINP, (5) RIA (Orion) (ng/mL), (6) automated immunoassay analyser (Roche Elecsys) (ng/mL) 
NTX/Cr, (7) Osteomark ELISA (nmol BCE/mmol creatinine), (8) Ortho Clinical ECI automated immunoassay (nmol BCE/mmol creatinine) 
sCTX, (9) CrossLaps ELISA (Nordic Bioscience), (6) automated immunoassay analyser (Roche Elecsys) (ng/mL) 
 
a, all assays done at 6 months except PINP which was done at 12 months 
b, CSR, case study report. 
  
 Table 3. Short-Term Changes in BTMs and Fracture Outcomes.  
 
^ƚƵĚǇEĂŵĞ ^ƚƵĚǇƌƵŐ 
dƌĞĂƚŵĞŶƚ ?WůĂĐĞďŽA?ŚĂŶŐĞDĞĚŝĂŶŝĨĨĞƌĞŶĐĞ ?EǁŝƚŚ
dD ? dƌĞĂƚŵĞŶƚǀƐWůĂĐĞďŽZZ 
ŽŶĞ>W PINP Edy ?ƌ sCTX sĞƌƚĞďƌĂů EŽŶ ?sĞƌƚĞďƌĂů ,ŝƉ 
>EW,^ ? ůĞŶĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ?  ? ? ? ?  ? ? ? ? 
&/dsZdZ>
&ZdhZ 
ůĞŶĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ) ? ? ? ? ? ? ? ? ? )  ? ? ? ?  ? ? ? ?  ? ? ? ? 
&/d>/E/>
&ZdhZ 
ůĞŶĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ) ? ? ? ? ? ? ? ? ? )  ? ? ? ?  ? ? ? ?  ? ? ? ? 
&K^/d ůĞŶĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? ? )  ? ?  ? ?  ? ? ? ?  ? ? ? ? 
DE ?^^dhz ůĞŶĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ?  ? ? 
KE /ďĂŶĚƌŽŶĂƚĞ ?ŽƌĂů )  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
/E/s /ďĂŶĚƌŽŶĂƚĞ ?ŝ ?ǀ ? )  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
,/W ZŝƐĞĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
sZd ?EKZd,
DZ/ 
ZŝƐĞĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
sZd ?Dh>d/ ?
Ed/KE> 
ZŝƐĞĚƌŽŶĂƚĞ  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
,KZ/KE ? ? ? ? ŽůĞĚƌŽŶŝĐĂĐŝĚ ?ŝ ?ǀ ? )  ? ? ? ? ? ? ? ? ? ) ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ? ? ?  ? ? ? ?  ? ? ? ? 
DKZ ZĂůŽǆŝĨĞŶĞ ?  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? )  ? ?  ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? 
'EZd/KE^ ƌǌŽǆŝĨĞŶĞ ?  ? ?  ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? )  ? ? ? ?  ? ? ? ?  ? ? ? ? 
PEARL Lasofoxifene*  ? ? ? ? ? ? ? ? ? ? )  ? ? ? ? ? ? ? ? ? ? )  ? ?  ? ? ? ? ? ? ? ? ? ? ) 0.64 0.84 0.78 
 
*Selective Estrogen Receptor Modulator (SERM) 
  
Table 4.  Meta-regression Summary for Short-term Changes in BTM and Fracture Risk Reduction  
 
 Vertebral Non-Vertebral Hip 
 number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value 
Bone ALP 11 (3284) 
0.82 
(0.50, 0.88) 
<0.001 12 (4615) 
0.33 
(0.00, 0.57) 
0.053 12 (653) 
0.17 
(0.00, 0.47) 
0.24 
PINP 7 (2780) 
0.75 
(0.17, 0.85) 
0.011 7 (4454) 
0.53 
(0.00, 0.73) 
0.065 7 (612) 
0.43 
(0.00, 0.67) 
0.11 
NTX/Cr 8 (1639) 
0.38 
(0.00, 0.64) 
0.10 9 (2500) 
0.25 
(0.00, 0.54) 
0.17 9 (366) 
0.03 
(0.00, 0.34) 
0.73 
sCTX 5 (1780) 
0.62 
(0.00, 0.78) 
0.11 5 (2865) 
0.47 
(0.00, 0.71) 
0.20 5 (350) 
0.20 
(0.00, 0.56) 
0.45 
 
For Bone ALP Ostase Tandem IRMA Assay and NTX/Cr with Osteomark ELISA Assay: 
 
 Vertebral Non-Vertebral Hip 
 number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value number of 
studies  
(N fracture) 
r2 
(95% CI) 
p value 
Bone ALP 7 (1701) 
0.52 
(0.00, 0.72) 
0.066 8 (2704) 
0.33 
(0.00, 0.61) 
0.13 8 (376) 
0.10 
(0.00, 0.47) 
0.53 
NTX/Cr 6 (1293) 
0.41 
(0.00, 0.67) 
0.17 7 (2244) 
0.31 
(0.00, 0.60) 
0.20 7 (334) 
0.03 
(0.00, 0.38) 
0.78 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The relationship between the odds ratio (for vertebral fracture) or the 
relative hazard (for non-vertebral and hip fracture) and the difference between 
treatment and placebo group in percentage change in BTM for the two bone 
formation markers. Larger circles indicate studies with more fractures, and the line 
represents log relative risk plotted against percent change. 
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Figure 2. The relationship between the odds ratio (for vertebral fracture) or the 
relative hazard (for non-vertebral and hip fracture) and the difference between 
treatment and placebo group in percentage change in BTM for the two bone 
resorption markers. Larger circles indicate studies with more fractures, and the line 
represents log relative risk plotted against percent change. 
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Figure 3. Estimated vertebral fracture risk reduction associated with small and large 
short-term changes in formation BTMs (data derived from Figure 1) 
 
